Shares of TransMedics Group (NASDAQ: TMDX) were tanking 14.3% lower as of 10:46 a.m. ET on Friday. The big sell-off came after activist short seller Scorpion Capital released a scathing report about TransMedics.
Scorpion stated in its report, “TransMedics is the most extreme and grotesque healthcare fraud we have encountered, not only for its scale, but because it is predicated on the exploitation of the most vulnerable patients — the terminally ill, desperate for an organ.” The short seller alleged that TransMedics overcharges for its services, bills fraudulently, “pushes unsafe, damaged organs rejected by reputable centers,” and uses unlicensed healthcare professionals, among other accusations.
Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day. Sign Up For Free »
Any allegations as serious as the ones Scorpion is making against TransMedics should be taken seriously. However, investors shouldn’t make a rash decision about selling shares until more information is available. TransMedics Group’s management had not responded publicly to Scorpion Capital’s report at the time of this writing.
Some of Scorpion’s allegations might seem questionable to anyone who has followed TransMedics. For example, the short seller stated that TransMedics is experiencing “an accelerating customer exodus, the fastest such stampede we have ever encountered.” But TransMedics reported a 64% year-over-year revenue increase in the third quarter of 2024.
Scorpion also claimed that TransMedics’ “device has no value proposition.” Yet clinical trials revealed significant increases in the utilization of donor organs for transplants using the company’s Organ Care System (OCS). Clinical outcomes were also much better with OCS.
Members of TransMedics Group’s management team are scheduled to speak at the J.P. Morgan Healthcare Conference on Monday, Jan. 13. This will allow executives to respond directly to Scorpion’s allegations if they choose to do so. I suspect they will address the allegations head-on. TransMedics shareholders and investors interested in the stock could then potentially have more information to decide their next steps.
Before you buy stock in TransMedics Group, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and TransMedics Group wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $858,668!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of January 6, 2025
Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.
—
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]
